Medical News

RSS

Researcher of LA BioMed elected to distinguished fellow status of SVS

Carlos E. Donayre, MD, a researcher at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), has been elected to distinguished fellow status of the Society for Vascular Surgery- (SVS).

20 Aug 2009

Vanderbilt enters Chemical Biology Consortium as a Chemical Diversity Center to develop cancer treatment drugs

Vanderbilt University has been selected as one of 10 centers in the nation to participate in the Chemical Biology Consortium (CBC), a major new initiative to facilitate the discovery and development of new agents to treat cancer.

20 Aug 2009

Surgeons of BMI of Texas selected to host a preceptorship for using REALIZE Adjustable Gastric Band

The Bariatric Medical Institute of Texas (“BMI of Texas”) today announced surgeons Mickey Seger and Terive Duperier have been selected by Ethicon Endo-Surgery, Inc. as one of the five training sites in the U.S. to host a preceptorship for the Ethicon Endo-Surgery REALIZE™ Adjustable Gastric Band.

20 Aug 2009

American Public University offers “Tips for Teachers” cards free of cost

“Tips for Teachers” cards on key behavioral and student wellness issues are available at no cost to teachers, counselors, principals and other school-based personnel, thanks to a program by American Public University, a member institution of American Public University System, an accredited, online university system that serves more than 50,000 working adults studying worldwide.

20 Aug 2009

Emisphere Technologies to sell securities for funding its operations

Emisphere Technologies, Inc. (OTC BB: EMIS) today announced that it has received commitments from two institutional investors to purchase $4 million of securities in a registered direct offering. Emisphere entered into a securities purchase agreement with these investors pursuant to which Emisphere has agreed to sell an aggregate of 5,714,286 shares of its common stock and warrants to purchase up to 2,685,714 additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase 0.47 of a share of common stock, will be sold for a purchase price of $0.70.

20 Aug 2009

US FDA announces establishment of the Center for Tobacco Products with Lawrence Deyton as Center Director

The U.S. Food and Drug Administration announcement today that it is establishing the Center for Tobacco Products and has selected Lawrence Deyton, MSPH, MD, a highly respected and experienced public health leader, as the Center Director is a demonstration of its commitment to moving quickly and vigorously to implement its new authority to regulate tobacco products, the leading preventable cause of death in the United States. This announcement comes just two months after Congress approved and President Obama signed into law historic legislation giving the FDA authority over tobacco products.

20 Aug 2009

Institutional investor buys $30 million of convertible stock and warrants in Cell Therapeutics

Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. Each share of Series 2 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 628 shares of common stock at a conversion price of $1.59125 per share of common stock for a total of approximately 18,853,103 common shares.

20 Aug 2009

WSNA launches new website as part of outreach campaign for health care reform

Washington State Nurses Association (WSNA), the professional organization representing more than 16,000 registered nurses in Washington State, has announced a new outreach and education campaign to support meaningful health care reform in 2009. Launching on Wednesday, August 19, the campaign will feature television ads across the Pacific Northwest and a new website, www.Nurses4HealthReform.org, with information and tools for both nurses and the general public to get involved in the health care debate.

20 Aug 2009

Official launch of the FocusUP website announced

HST Global, Inc. today announced the official launch of the FocusUP® Website located at www.focusup.com FocusUP is the cognitive function product endorsed and recommended by Dr. Kyl Smith under a Joint Venture with Dalham, LLC (an affiliate company of The Health Network, Inc.).

20 Aug 2009

Weikang Bio-Technology Group announces increased revenues for second-quarter of 2009

Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT; "WKBT"), a Chinese producer of OTC pharmaceuticals and traditional Chinese medicine ("TCM") products, reported financial results for its second quarter ended June 30, 2009.

20 Aug 2009

Diarrhea remains second leading cause of death among children, despite effective interventions

Despite the introduction of new treatments for diarrhea more than four years ago, few children in developing countries are receiving these interventions and the disease is still the second leading cause of death among children, according a Bulletin of the World Health Organization report, BMJ reports.

20 Aug 2009

Shortage of medical isotopes could affect the health of Canadians

Canada's physicians are deeply troubled about the prolonged and unpredictable shortage of medical isotopes and impact the crisis continues to have on patient care.

20 Aug 2009

U.S.District Court ruling favors Merck in patent infringement suit against Teva Pharmaceuticals

Merck & Co., Inc. announced today that the U.S. District Court for the District of New Jersey has ruled in Merck's favor in a patent infringement suit against Teva Pharmaceuticals USA Inc. (Teva).

20 Aug 2009

Perot Systems to provide back-office functional support to Community Health Plan of Washington

Community Health Plan of Washington (CHP Washington) and Perot Systems Corporation (NYSE: PER) (www.perotsystems.com) today announced an agreement where Perot Systems will provide technology and business process services to improve the Seattle-based health plan's back-office functions. The scope of services to be managed by Perot Systems includes claims processing, claims adjustments, enrollment, premium billing, and configuration.

20 Aug 2009

Amphion Innovations reports interim results for the six months ended 30 June 2009

Amphion Innovations plc (LSE: AMP) (“Amphion” or the “Company”), the developer of medical and technology businesses, today announces its unaudited interim results for the six months to 30 June 2009.

20 Aug 2009

Blankenships receive $6 million compensation for infant son's death due to medical negligence

A couple who alleged that Saint Louis University failed to diagnose and treat a bacterial infection that led to their 6-month-old son’s death were awarded $6 million by a St. Louis jury on Aug. 17. The parents were represented by attorneys David M. Zevan and Kevin J. Davidson of St. Louis-based Zevan & Davidson.

20 Aug 2009

Aton Pharma markets preservative-free drugs for glaucoma

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.

20 Aug 2009

Bay Bio joins business leaders to promote research, innovation and development in California

BayBio, Northern California’s life sciences association, joins business leaders at the State Capital to promote innovation, research and development as a cost-effective building block to the Golden State’s economic future. The coalition calls on policymakers to make a concerted effort to develop a manufacturing policy to capture the potential the life sciences offers to California workers.

20 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Catalent Pharma Solutions completes the first FDA general cGMP audit

Catalent Pharma Solutions announces the recent successful completion of the first FDA general cGMP audit and pre-approval inspection of its Buenos Aires, Argentina pharmaceutical softgel facility, with no reported observations on FDA Form 483.

20 Aug 2009

Medical News

Researcher of LA BioMed elected to distinguished fellow status of SVS

Vanderbilt enters Chemical Biology Consortium as a Chemical Diversity Center to develop cancer treatment drugs

Surgeons of BMI of Texas selected to host a preceptorship for using REALIZE Adjustable Gastric Band

American Public University offers “Tips for Teachers” cards free of cost

Emisphere Technologies to sell securities for funding its operations

US FDA announces establishment of the Center for Tobacco Products with Lawrence Deyton as Center Director

Institutional investor buys $30 million of convertible stock and warrants in Cell Therapeutics

WSNA launches new website as part of outreach campaign for health care reform

Official launch of the FocusUP website announced

Weikang Bio-Technology Group announces increased revenues for second-quarter of 2009

Diarrhea remains second leading cause of death among children, despite effective interventions

Shortage of medical isotopes could affect the health of Canadians

U.S.District Court ruling favors Merck in patent infringement suit against Teva Pharmaceuticals

Perot Systems to provide back-office functional support to Community Health Plan of Washington

Amphion Innovations reports interim results for the six months ended 30 June 2009

Blankenships receive $6 million compensation for infant son's death due to medical negligence

Aton Pharma markets preservative-free drugs for glaucoma

Bay Bio joins business leaders to promote research, innovation and development in California

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Catalent Pharma Solutions completes the first FDA general cGMP audit

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News